Our CEO, Nigel Theobald, is featured in the June issue of The Medicine Maker reviewing the progress made with #covid19vaccines so far.

He also looks at how silica nanoparticles like Nuvec® can help to overcome some of the delivery issues that we’ve seen in the vaccines developed to date.

“Now that several vaccines have reached the market and many others are in development, I feel it’s a good time to take stock of where we are – and, more importantly, where we are going. And I think it is also important to make the distinction between efficacy (reduction of disease) and effectiveness (ability to achieve immunity in the mass population) of the vaccines that are available and being developed. We must also consider what lessons can be learnt as we plan the future management of this (and other) contagious disease outbreaks.” 

Read the article online now: https://bit.ly/3i7zkgD and look out for it in the June print issue of the magazine.